Multisystem inflammatory syndrome in children (mis-c) post infection sars-cov-2: a literature review

The number of COVID-19 instances involving children or adolescents is quite low. However, occurrences in children and adolescents are either not clinically identified or are modest due to silent infections. Multisystem Inflammatory Syndrome in Children (MIS-C) cases have been documented frequently throughout the past pandemic. MIS-C is an immune-mediated post-infectious process that develops autoantibodies and can be associated with many specificities. Increased levels of numerous plasma cytokines, such as IL-6, IL-8, IFN-γ, IL-17, TNF-α, and IL-10, as well as modifications to the interferon response pathway are present in patients with MIS-C. The majority of patients have a fever that lasts for more than 4 days, and typical symptoms include conjunctivitis, rash, and mucocutaneous symptoms like conjunctivitis, as well as neurologic abnormalities like headache, irritability, and encephalopathy. Management strategies based on particular symptoms, therapies for disorders with a similar presentation, such as Kawasaki disease, or recommendations for COVID-19 treatment in individuals over the age of 18. Patients who got corticosteroids together with IVIG recovered more quickly than patients who did not. Fewer MIS-C is self-limiting and may get better with just supportive treatment.